Menno Tamminga1, Sanne de Wit2, Ed Schuuring3, Wim Timens3, Leon W M M Terstappen2, T Jeroen N Hiltermann1, Harry J M Groen1. 1. Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. Department of Medical Cell BioPhysics, Faculty of Sciences and Technology, University of Twente, Enschede, The Netherlands. 3. Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: It is unknown whether the presence of circulating tumor cells (CTC), a known prognostic factor, influences treatment outcome. We investigated whether baseline CTC in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors (TKI) or chemotherapy was associated with response to therapy. METHODS: We included consecutive advanced NSCLC patients, stratified by therapy. Before treatment the number of CTC was measured by CellSearch. Tumor response rates, progression free survival (PFS) and overall survival (OS) in patients with and without CTC at baseline were compared. RESULTS: We included 86 patients (34 treated by TKI). Response rates of patients with CTC were lower than in patients without CTC (OR =0.22, P<0.01, adjusted for performance score and smoking status). In both treatment groups, the difference in response rates between patients with and without CTC was similar (TKI response: 25% with CTC versus 73% without CTC, chemotherapy response: 35% versus 51% respectively, interaction P=0.17). CTC was associated with a worse PFS [hazard ratio (HR) =2.0, 95% confidence interval (CI): 1.2-3.2, P=0.01] and OS (HR =1.7, 95% CI: 1.1-2.8, P=0.03) after adjustment for performance score and stage. The association remained significant after adding tumor response to the model (PFS: HR =1.9, 95% CI: 1.0-3.0, P=0.01, OS: HR =1.6, 95% CI: 1.0-2.6, P=0.05). No significant interaction between CTC presence and therapy was observed (P=0.42 for PFS and P=0.83 for OS). CONCLUSIONS: Presence of CTC in advanced NSCLC patients is associated with low response rates, shorter PFS and OS, independent of the received therapy. 2019 Translational Lung Cancer Research. All rights reserved.
BACKGROUND: It is unknown whether the presence of circulating tumor cells (CTC), a known prognostic factor, influences treatment outcome. We investigated whether baseline CTC in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors (TKI) or chemotherapy was associated with response to therapy. METHODS: We included consecutive advanced NSCLC patients, stratified by therapy. Before treatment the number of CTC was measured by CellSearch. Tumor response rates, progression free survival (PFS) and overall survival (OS) in patients with and without CTC at baseline were compared. RESULTS: We included 86 patients (34 treated by TKI). Response rates of patients with CTC were lower than in patients without CTC (OR =0.22, P<0.01, adjusted for performance score and smoking status). In both treatment groups, the difference in response rates between patients with and without CTC was similar (TKI response: 25% with CTC versus 73% without CTC, chemotherapy response: 35% versus 51% respectively, interaction P=0.17). CTC was associated with a worse PFS [hazard ratio (HR) =2.0, 95% confidence interval (CI): 1.2-3.2, P=0.01] and OS (HR =1.7, 95% CI: 1.1-2.8, P=0.03) after adjustment for performance score and stage. The association remained significant after adding tumor response to the model (PFS: HR =1.9, 95% CI: 1.0-3.0, P=0.01, OS: HR =1.6, 95% CI: 1.0-2.6, P=0.05). No significant interaction between CTC presence and therapy was observed (P=0.42 for PFS and P=0.83 for OS). CONCLUSIONS: Presence of CTC in advanced NSCLC patients is associated with low response rates, shorter PFS and OS, independent of the received therapy. 2019 Translational Lung Cancer Research. All rights reserved.
Authors: Maria A Papadaki; Giannis Stoupis; Panayiotis A Theodoropoulos; Dimitris Mavroudis; Vassilis Georgoulias; Sofia Agelaki Journal: Mol Cancer Ther Date: 2018-11-06 Impact factor: 6.261
Authors: Sanne de Wit; Elisabetta Rossi; Sabrina Weber; Menno Tamminga; Mariangela Manicone; Joost F Swennenhuis; Catharina G M Groothuis-Oudshoorn; Riccardo Vidotto; Antonella Facchinetti; Leonie L Zeune; Ed Schuuring; Rita Zamarchi; T Jeroen N Hiltermann; Michael R Speicher; Ellen Heitzer; Leon W M M Terstappen; Harry J M Groen Journal: Int J Cancer Date: 2019-01-28 Impact factor: 7.396
Authors: A J van der Wekken; R Pelgrim; N 't Hart; N Werner; M F Mastik; L Hendriks; E H F M van der Heijden; M Looijen-Salamon; A J de Langen; J Staal-van den Brekel; S Riemersma; B E van den Borne; E J M Speel; A-M C Dingemans; T J N Hiltermann; A van den Berg; W Timens; E Schuuring; H J M Groen Journal: Clin Cancer Res Date: 2017-02-09 Impact factor: 12.531
Authors: Antonio Marchetti; John F Palma; Lara Felicioni; Tommaso M De Pas; Rita Chiari; Maela Del Grammastro; Giampaolo Filice; Vienna Ludovini; Alba A Brandes; Antonio Chella; Francesco Malorgio; Flavio Guglielmi; Michele De Tursi; Armando Santoro; Lucio Crinò; Fiamma Buttitta Journal: J Thorac Oncol Date: 2015-10 Impact factor: 15.609
Authors: Massimo Cristofanilli; Daniel F Hayes; G Thomas Budd; Mathew J Ellis; Alison Stopeck; James M Reuben; Gerald V Doyle; Jeri Matera; W Jeffrey Allard; M Craig Miller; Herbert A Fritsche; Gabriel N Hortobagyi; Leon W M M Terstappen Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: T J N Hiltermann; M M Pore; A van den Berg; W Timens; H M Boezen; J J W Liesker; J H Schouwink; W J A Wijnands; G S M A Kerner; F A E Kruyt; H Tissing; A G J Tibbe; L W M M Terstappen; H J M Groen Journal: Ann Oncol Date: 2012-06-11 Impact factor: 32.976
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: Sanne de Wit; Guus van Dalum; Aufried T M Lenferink; Arjan G J Tibbe; T Jeroen N Hiltermann; Harry J M Groen; Cees J M van Rijn; Leon W M M Terstappen Journal: Sci Rep Date: 2015-07-17 Impact factor: 4.379
Authors: Menno Tamminga; Kiki C Andree; Hilda van den Bos; T Jeroen N Hiltermann; Anouk Mentink; Diana C J Spierings; Peter Lansdorp; Wim Timens; Ed Schuuring; Leon W M M Terstappen; Harry J M Groen Journal: Br J Cancer Date: 2021-11-30 Impact factor: 7.640
Authors: Menno Tamminga; Lisa Oomens; T Jeroen N Hiltermann; Kiki C Andree; Arjan Tibbe; Joska Broekmaat; Ed Schuuring; Leon W M M Terstappen; Harry J M Groen Journal: Transl Lung Cancer Res Date: 2020-08